Sysmex Corp : Sysmex to Begin Offering Laboratory Testing Service for Research Involving the Risk of Recurrence of Early-Stage Breast Cancer -Working to Achieve Personalized Medicine-
January 30, 2012 at 06:51 am
By
Share
Sysmex Corporation (HQ: Kobe, Japan; President:
Hisashi Ietsugu) will begin offering in Japan in January 31 a
new laboratory service (for research) related to the risk of
recurrence of early-stage breast cancer.
In recent years, changing eating habits and other
lifestyle changes in Japan have led to ongoing increases in
the number of breast cancer patients. Determining the
post-operative risk of recurrence is considered to be an
important indicator in the treatment of breast cancer. The
selection of treatment methods involves an overall judgment
based on a variety of test results. Anti-cancer drugs and
other treatments are employed after determining the
post-operative risk of recurrence.
Sysmex's new laboratory service for research
(C2P Breast) will involve a new technology (C2P: Cell Cycle
Profiling) developed through joint research and performance
evaluation tests conducted with university hospitals and
other institutions. Measurement will involve studying the
expression amounts of two types of proteins included in tumor
tissue removed from the patient as well as their enzyme
activity. In principle, these results will then be
categorized into three stages (H: High; I: Intermediate; and
L: Low).
Our procedure for undertaking this service will be to
have customers (hospitals) send us frozen samples of
patients' tumor tissue in special test transport kits.
Sysmex will measure the samples and report the results to
customers (hospitals). We expect to report these results
within two to three weeks of receiving the samples.
Sysmex's Group Mid-Term Management Plan
includes three core strategies*. Based on one of these core
strategies, "Innovating Life Science," we aim to
create proprietary testing technologies in the life sciences
field, expanding our operations in cancer and other areas of
molecular diagnostics.
To date, Sysmex has developed a highly precise
technology (the OSNA method, for One-step Nucleic Acid
Amplification) for determining the existence of breast cancer
lymph node metastasis in only around 30 minutes. We have
introduced products employing this technology at numerous
healthcare facilities.
Going forward, Sysmex will continue working to develop and
promote high-value testing that will contribute to
improvements in quality of life (QOL) for patients, the
standardization of medical services and the development of
personalized medicine.
Sysmex Corp is a Japan-based company principally engaged in the health care business. The Company conducts product development, manufacturing, sales, and service in domestic markets, and some products are developed, manufactured, and sold by subsidiaries. Overseas, the Company conducts the manufacturing and sales of products in the Americas, EMEA, China, and Asia Pacific through other companies. Along with its subsidiaries, the Company is involved in the development, manufacture, sale and service of clinical laboratory equipment, laboratory test drugs and products related to laboratory test.
Sysmex Corp : Sysmex to Begin Offering Laboratory Testing Service for Research Involving the Risk of Recurrence of Early-Stage Breast Cancer -Working to Achieve Personalized Medicine-
SYSMEX CORPORATION 
By 
